Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2013 1
2015 1
2018 1
2020 1
2021 1
2023 1
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.
The NAMS 2020 GSM Position Statement Editorial Panel. The NAMS 2020 GSM Position Statement Editorial Panel. Menopause. 2020 Sep;27(9):976-992. doi: 10.1097/GME.0000000000001609. Menopause. 2020. PMID: 32852449
OBJECTIVE: To update and expand the 2013 position statement of The North American Menopause Society (NAMS) on the management of the genitourinary syndrome of menopause (GSM), of which symptomatic vulvovaginal atrophy (VVA) is a component. ...Nonhormone …
OBJECTIVE: To update and expand the 2013 position statement of The North American Menopause Society (NAMS) on the management o …
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, Thurston RC, English M, Franklin C, Lee M, Neal-Perry G. Lederman S, et al. Lancet. 2023 Apr 1;401(10382):1091-1102. doi: 10.1016/S0140-6736(23)00085-5. Epub 2023 Mar 13. Lancet. 2023. PMID: 36924778 Clinical Trial.
BACKGROUND: Neurokinin 3 receptor antagonists are potential non-hormonal therapies for the treatment of vasomotor symptoms in menopausal women as options are scarce for those who cannot or do not want to take hormone therapy. Fezolinetant is one of the first …
BACKGROUND: Neurokinin 3 receptor antagonists are potential non-hormonal therapies for the treatment of vasomotor symptoms in meno …
Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health.
Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, Kaunitz AM, Krychman ML, Parish SJ, Partridge AH, Pinkerton JV, Rowen TS, Shapiro M, Simon JA, Goldfarb SB, Kingsberg SA. Faubion SS, et al. Menopause. 2018 Jun;25(6):596-608. doi: 10.1097/GME.0000000000001121. Menopause. 2018. PMID: 29762200
The objective of The North American Menopause Society (NAMS) and The International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel was to create a point of care algorithm for treating genitourinary syndrome of menopause (GSM) in …
The objective of The North American Menopause Society (NAMS) and The International Society for the Study of Women's Sexual Hea …
Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society.
[No authors listed] [No authors listed] Menopause. 2015 Nov;22(11):1155-72; quiz 1173-4. doi: 10.1097/GME.0000000000000546. Menopause. 2015. PMID: 26382310
OBJECTIVE: To update and expand The North American Menopause Society's evidence-based position on nonhormonal management of menopause-associated vasomotor symptoms (VMS), previously a portion of the position statement on the management of VMS. ...Nonhormon …
OBJECTIVE: To update and expand The North American Menopause Society's evidence-based position on nonhormonal management of …
Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management.
Guo ZQ. Guo ZQ. Front Reprod Health. 2025 Nov 13;7:1694240. doi: 10.3389/frph.2025.1694240. eCollection 2025. Front Reprod Health. 2025. PMID: 41323403 Free PMC article. Review.
Pharmacological management is essential for symptom alleviation and long-term health, yet debates on hormone therapy risks necessitate personalized approaches. This review synthesizes recent advances in menopause pharmacology, evaluating hormonal therapies, n …
Pharmacological management is essential for symptom alleviation and long-term health, yet debates on hormone therapy risks necessitat …
[Genitourinary menopause syndrome. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines].
Hocké C, Diaz M, Bernard V, Frantz S, Lambert M, Mathieu C, Grellety-Cherbero M. Hocké C, et al. Gynecol Obstet Fertil Senol. 2021 May;49(5):394-413. doi: 10.1016/j.gofs.2021.03.025. Epub 2021 Mar 20. Gynecol Obstet Fertil Senol. 2021. PMID: 33757926 French.
INTRODUCTION: Genitourinary menopause syndrome (SGUM) is defined as a set of symptoms associated with a decrease of estrogen and other sexual steroids during menopause. ...Recommendations from international scholarly societies were also taken into account: Internati …
INTRODUCTION: Genitourinary menopause syndrome (SGUM) is defined as a set of symptoms associated with a decrease of estrogen and othe …
Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.
North American Menopause Society. North American Menopause Society. Menopause. 2004 Jan-Feb;11(1):11-33. doi: 10.1097/01.GME.0000108177.85442.71. Menopause. 2004. PMID: 14716179
OBJECTIVE: To create an evidence-based position statement regarding the treatment of vasomotor symptoms associated with menopause. DESIGN: The North American Menopause Society (NAMS) enlisted clinicians and researchers acknowledged to be experts in the field …
OBJECTIVE: To create an evidence-based position statement regarding the treatment of vasomotor symptoms associated with menopause. DE …
Case-Based Perspectives on the Management of Genitourinary Syndrome of Menopause.
Cyriac J, Sood R. Cyriac J, et al. Clin Pract. 2026 Mar 12;16(3):60. doi: 10.3390/clinpract16030060. Clin Pract. 2026. PMID: 41892504 Free PMC article. Review.
MATERIALS AND METHODS: Evidence was drawn from multiple sources through targeted searches of databases, and included the 2025 AUA/SUFU/AUGS guideline (AUA), the 2024 NICE network meta-analyses (NICE), a 2025 systematic review/meta-analysis in breast-cancer survivors, the 2020 …
MATERIALS AND METHODS: Evidence was drawn from multiple sources through targeted searches of databases, and included the 2025 AUA/SUFU/AUGS …
Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
[No authors listed] [No authors listed] Menopause. 2013 Sep;20(9):888-902; quiz 903-4. doi: 10.1097/GME.0b013e3182a122c2. Menopause. 2013. PMID: 23985562
OBJECTIVE: To update and expand the previous position statement of The North American Menopause Society (NAMS) on the management of symptomatic vulvovaginal atrophy (VVA) in postmenopausal women. ...Nonhormonal therapies available without a prescriptio …
OBJECTIVE: To update and expand the previous position statement of The North American Menopause Society (NAMS) on the manageme …